Abiraterone acetate is prescribed for men with metastatic castration-resistant prostate cancer (mCRPC). It is often used in combination with prednisone to reduce side effects and improve efficacy. It may be prescribed after other treatments, such as chemotherapy, have failed, or it may be used earlier in the treatment regimen depending on the specific case.
